Cargando…
TYK2 promotes malignant peripheral nerve sheath tumor progression through inhibition of cell death
BACKGROUND: Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas that arise most commonly in the setting of the Neurofibromatosis Type 1 (NF1) cancer predisposition syndrome. Despite aggressive multimodality therapy, outcomes are dismal and most patients die within 5 years of di...
Autores principales: | Qin, Wenjing, Godec, Abigail, Zhang, Xiaochun, Zhu, Cuige, Shao, Jieya, Tao, Yu, Bu, Xianzhang, Hirbe, Angela C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718590/ https://www.ncbi.nlm.nih.gov/pubmed/31278855 http://dx.doi.org/10.1002/cam4.2386 |
Ejemplares similares
-
MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
por: Borcherding, Dana C., et al.
Publicado: (2023) -
Photonic hyperthermia of malignant peripheral nerve sheath tumors at the third near-infrared biowindow
por: Gu, Yihui, et al.
Publicado: (2022) -
Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma
por: Mattox, Austin K, et al.
Publicado: (2022) -
Neoadjuvant Ifosfamide and Epirubicin in the Treatment of Malignant Peripheral Nerve Sheath Tumors
por: Hirbe, Angela C., et al.
Publicado: (2017) -
Diagnosis and management of malignant peripheral nerve sheath tumors: Current practice and future perspectives
por: Prudner, Bethany C, et al.
Publicado: (2019)